Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

161. Prevalence, Mortality, and Indicators of Health Care Supply—Association Analysis of Cardiovascular Diseases in Germany Full Text available with Trip Pro

Prevalence, Mortality, and Indicators of Health Care Supply—Association Analysis of Cardiovascular Diseases in Germany Introduction: There are regional differences in the morbidity of major cardiovascular disease between the 16 federal states of Germany. An association between the morbidity and the health care supply has been described in international studies. The aim of the present analysis was to examine the relationship between the prevalence or mortality of major cardiovascular disease (...) disease prevalence and mortality with these indicators and performed a weighted linear regression. Results: Regional variations between the federal states were found in general health and health care supply. The regression analysis yielded significant associations of the prevalence of major cardiovascular disease with the number of internal medicine hospital beds (β = 10.042, p = 0.045), cardiologists (β = -0.689, p = 0.031), and the number of residents per chest pain unit (β = 42,730, p = 0.036

2018 Frontiers in cardiovascular medicine

162. Population surveillance of cardiovascular diseases in low-income to middle-income countries should leverage existing international collaborations Full Text available with Trip Pro

Population surveillance of cardiovascular diseases in low-income to middle-income countries should leverage existing international collaborations 30294457 2018 11 14 2059-7908 3 5 2018 BMJ global health BMJ Glob Health Population surveillance of cardiovascular diseases in low-income to middle-income countries should leverage existing international collaborations. e000866 10.1136/bmjgh-2018-000866 Echouffo-Tcheugui Justin B JB Brigham and Women's Hospital, Harvard Medical School, Boston (...) Wales, Sydney, Australia. Non-communicable Diseases Research Unit, South African Medical Research Council & University of Cape Town, Cape Town, South Africa. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. eng Journal Article 2018 10 01 England BMJ Glob Health 101685275 2059-7908 control strategies prevention strategies public health Competing interests: None declared. 2018 04 03 2018 08 15 2018 10 9 6 0 2018 10 9 6 0 2018 10 9 6 1

2018 BMJ global health

163. Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Canadian Cardiovascular Harmonized National Guidelines Endeavour (C (...) -CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update Sheldon W. Tobe , James A. Stone , Todd Anderson , Simon Bacon , Alice Y.Y. Cheng , Stella S. Daskalopoulou , Justin A. Ezekowitz , Jean C. Gregoire , Gord Gubitz , Rahul Jain , Karim Keshavjee , Patty Lindsay , Mary L’Abbe , David C.W. Lau , Lawrence A. Leiter , Eileen O’Meara , Glen J. Pearson , Doreen M. Rabi , Diana Sherifali , Peter Selby , Jack V. Tu , Sean Wharton , Kimberly M. Walker

2018 CPG Infobase

164. Cardiovascular Health in Turner Syndrome: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Kadian-Dodov , Leo Lopez , Kristian H. Mortensen , Siddharth K. Prakash , Elizabeth V. Ratchford , Arwa Saidi , Iris van Hagen , Luciana T. Young , and Originally published 24 Sep 2018 Circulation: Genomic and Precision Medicine. 2018;11 Abstract Girls and women with Turner syndrome face a lifelong struggle with both congenital heart disease and acquired cardiovascular conditions. Bicuspid aortic valve is common, and many have left-sided heart obstructive disease of varying severity, from hypoplastic (...) left-sided heart syndrome to minimal aortic stenosis or coarctation of the aorta. Significant enlargement of the thoracic aorta may progress to catastrophic aortic dissection and rupture. It is becoming increasingly apparent that a variety of other cardiovascular conditions, including early-onset hypertension, ischemic heart disease, and stroke, are the major factors reducing the life span of those with Turner syndrome. The presentations and management of cardiovascular conditions in Turner

2018 American Heart Association

165. Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial (Abstract)

Tai Chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial Physical inactivity is a major modifiable lifestyle risk factor associated with cardiovascular disease. Tai Chi is a safe and popular form of physical activity among older adults, yet direct comparisons are lacking between Tai Chi and brisk walking in their ability to reduce cardiovascular disease risk factors and improve (...) psychosocial well-being.246 adults (mean age = 64.4 ± 9.8 years, age range = 30-91 years, 45.5% men) with hypertension and at least two but not more than three modifiable cardiovascular disease risk factors (diabetes, dyslipidaemia, overweight, physical inactivity and smoking) were randomly assigned to either Tai Chi (n = 82), brisk walking (n = 82) or control (n = 82) groups. The Tai Chi and brisk walking groups engaged in moderate-intensity physical activity 150 min/week for 3 months; daily home-based

2018 EvidenceUpdates

166. The Metabolic Syndrome, Cardiovascular Fitness and Survival in Patients With Advanced Systolic Heart Failure (Abstract)

The Metabolic Syndrome, Cardiovascular Fitness and Survival in Patients With Advanced Systolic Heart Failure The metabolic syndrome (MetS), which incorporates insulin resistance, visceral adiposity, and dyslipidemia, is an independent risk factor for incident heart failure (HF), but the impact on survival is uncertain. We sought to determine the relation between the metabolic syndrome and survival in ambulatory systolic HF patients and the impact of MetS on cardiopulmonary exercise test (CPET

2018 EvidenceUpdates

167. Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy (Abstract)

Cardiovascular risk model performance in women with and without hypertensive disorders of pregnancy Compare the predictive performance of Framingham Risk Score (FRS), Pooled Cohort Equations (PCEs) and Systematic COronary Risk Evaluation (SCORE) model between women with and without a history of hypertensive disorders of pregnancy (hHDP) and determine the effects of recalibration and refitting on predictive performance.We included 29 751 women, 6302 with hHDP and 17 369 without. We assessed (...) whether models accurately predicted observed 10-year cardiovascular disease (CVD) risk (calibration) and whether they accurately distinguished between women developing CVD during follow-up and not (discrimination), separately for women with and without hHDP. We also recalibrated (updating intercept and slope) and refitted (recalculating coefficients) the models.Original FRS and PCEs overpredicted 10-year CVD risks, with expected:observed (E:O) ratios ranging from 1.51 (for FRS in women with hHDP

2018 EvidenceUpdates

168. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Full Text available with Trip Pro

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death (...) , myocardial infarction, or stroke.We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30-50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web

2018 Lancet Controlled trial quality: predicted high

169. PON-1 Q192R (rs662) Gene Polymorphism and the Risk of Major Adverse Cardiovascular Events in Clopidogrel-Treated Patients with Coronary Heart Disease: A Systematic Review and Meta-Analysis Full Text available with Trip Pro

PON-1 Q192R (rs662) Gene Polymorphism and the Risk of Major Adverse Cardiovascular Events in Clopidogrel-Treated Patients with Coronary Heart Disease: A Systematic Review and Meta-Analysis PON 1 Q192R rs662 Gene Polymorphism and The Risk of Major Adverse Cardiovascular Events in Clopidogrel Treated Patients with Coronary Heart Disease | Ocimum Scientific Publishers Go! Journal of Cardiology and Catheterization Share Article Quick Links Original Research PON-1 Q192R (rs662) Gene Polymorphism (...) and the Risk of Major Adverse Cardiovascular Events in Clopidogrel-Treated Patients with Coronary Heart Disease: A Systematic Review and Meta-Analysis Ling-Yun Zhou 1 , Long Shen 2 , Xiao-Cong Zuo 1 and Zhi-Chun Gu 3,4* 1 Clinical Pharmacy and Pharmacology Research Institute, Third Xiangya Hospital, Central South University, China 2 Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China 3 Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai

2018 https://ocimumpublishers.com/journal/cardiology-catheterization/present-issue

170. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Full Text available with Trip Pro

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The use of aspirin in the primary prevention of cardiovascular events remains controversial. We aimed to assess the efficacy and safety of aspirin versus placebo in patients with a moderate estimated risk of a first cardiovascular event.ARRIVE is a randomised, double-blind, placebo-controlled, multicentre study done (...) in seven countries. Eligible patients were aged 55 years (men) or 60 years (women) and older and had an average cardiovascular risk, deemed to be moderate on the basis of the number of specific risk factors. We excluded patients at high risk of gastrointestinal bleeding or other bleeding, or diabetes. Patients were randomly assigned (1:1) with a computer-generated randomisation code to receive enteric-coated aspirin tablets (100 mg) or placebo tablets, once daily. Patients, investigators, and others

2018 Lancet

171. Editorial: Extracellular Vesicle-Mediated Processes in Cardiovascular Diseases Full Text available with Trip Pro

Editorial: Extracellular Vesicle-Mediated Processes in Cardiovascular Diseases 30283791 2019 02 02 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Editorial: Extracellular Vesicle-Mediated Processes in Cardiovascular Diseases. 133 10.3389/fcvm.2018.00133 Koenen Rory R RR Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands. Aikawa Elena E Cardiovascular Division, Department of Medicine, Center

2018 Frontiers in cardiovascular medicine

172. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. (Abstract)

Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Dietary guidelines recommend minimising consumption of whole-fat dairy products, as they are a source of saturated fats and presumed to adversely affect blood lipids and increase cardiovascular disease and mortality. Evidence for this contention is sparse and few data for the effects of dairy consumption on health are available from low-income and middle (...) events (deaths [n=6796] or major cardiovascular events [n=5855]) during the 9·1 years of follow-up. Higher intake of total dairy (>2 servings per day compared with no intake) was associated with a lower risk of the composite outcome (HR 0·84, 95% CI 0·75-0·94; ptrend=0·0004), total mortality (0·83, 0·72-0·96; ptrend=0·0052), non-cardiovascular mortality (0·86, 0·72-1·02; ptrend=0·046), cardiovascular mortality (0·77, 0·58-1·01; ptrend=0·029), major cardiovascular disease (0·78, 0·67-0·90; ptrend=0

2018 Lancet

173. Management of Cardiovascular Diseases during Pregnancy Full Text available with Trip Pro

, maternal heart disease is the major cause of maternal death during pregnancy. , Hypertensive disorders are the most frequent cardiovascular disorders during pregnancy, occurring in 5–10% of all pregnancies (see section 10). Among the other disease conditions, congenital heart disease is the most frequent CVD present during pregnancy in the western world (75–82%). , Rheumatic valvular disease dominates in non-western countries, comprising 56–89% of all CVDs in pregnancy. , Peripartum intensive care unit (...) for recommending a healthy lifestyle, including smoking cessation. 3.3.1 Risk of maternal cardiovascular complications The risk of complications in pregnancy depends on the underlying cardiac diagnosis, ventricular and valvular function, functional class, presence of cyanosis, pulmonary artery pressures, and other factors. Comorbidities, including for example rheumatoid and musculoskeletal diseases as well as mental disorders, should also be taken into account. Therefore, risk estimation should

2018 European Society of Cardiology

174. Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks Full Text available with Trip Pro

Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks The field of extracellular vesicles (EV) is rapidly expanding, also within cardiovascular diseases. Besides their exciting roles in cell-to-cell communication, EV have the potential to serve as excellent biomarkers, since their counts, content, and origin might provide useful information about the pathophysiology of cardiovascular disorders. Various studies have already indicated associations of EV counts (...) and content with cardiovascular diseases. However, EV research is complicated by several factors, most notably the small size of EV. In this review, the advantages and drawbacks of EV-related methods and applications as biomarkers are highlighted.

2018 Frontiers in cardiovascular medicine

175. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Full Text available with Trip Pro

Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. People with type 1 diabetes are at elevated risk of mortality and cardiovascular disease, yet current guidelines do not consider age of onset as an important risk stratifier. We aimed to examine how age at diagnosis of type 1 diabetes relates to excess mortality and cardiovascular risk.We did a nationwide, register-based cohort study (...) of individuals with type 1 diabetes in the Swedish National Diabetes Register and matched controls from the general population. We included patients with at least one registration between Jan 1, 1998, and Dec 31, 2012. Using Cox regression, and with adjustment for diabetes duration, we estimated the excess risk of all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, acute myocardial infarction, stroke, cardiovascular disease (a composite of acute myocardial infarction and stroke

2018 Lancet

176. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. (Abstract)

Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. WHO recommends that populations consume less than 2 g/day sodium as a preventive measure against cardiovascular disease, but this target has not been achieved in any country. This recommendation is primarily based on individual-level data from short-term trials of blood pressure (BP) without data relating low sodium intake to reduced cardiovascular events (...) from randomised trials or observational studies. We investigated the associations between community-level mean sodium and potassium intake, cardiovascular disease, and mortality.The Prospective Urban Rural Epidemiology study is ongoing in 21 countries. Here we report an analysis done in 18 countries with data on clinical outcomes. Eligible participants were adults aged 35-70 years without cardiovascular disease, sampled from the general population. We used morning fasting urine to estimate 24 h

2018 Lancet

177. Remote ECG interpretation consultancy services for cardiovascular disease

services for cardiovascular disease (MIB152) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 16Express Diagnostics NHS email. SCST-accredited data analyst's report with pathway recommendation. ** Same day; up to 10 days. ** Supplies/ leases third- party devices. 12-lead, Holter. ECG On- Demand Automatic – digitally with NHS email or webpage upload. SCST-accredited cardiac physiologist's written report with level (...) assistant would record the ECG and then transmit the results to a remote location for interpretation. The consultancy service would then send a report back to the GP or nurse, with a recommendation for treatment. Training may be needed for GPs to learn how to transmit the recorded ECGs and receive the reports. Remote ECG interpretation consultancy services for cardiovascular disease (MIB152) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions

2018 National Institute for Health and Clinical Excellence - Advice

178. Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT) Full Text available with Trip Pro

Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT) Routinely collected data from large population health surveys linked to chronic disease outcomes create an opportunity to develop more complex risk-prediction algorithms. We developed a predictive algorithm to estimate 5-year risk of incident cardiovascular disease in the community setting.We derived the Cardiovascular Disease (...) ; women: 0.86, 95% CI 0.85-0.87) and was well-calibrated in the overall population (5-year observed cumulative incidence function v. predicted risk, men: 0.28%; women: 0.38%) and in nearly all predefined policy-relevant subgroups (206 of 208 groups).The CVDPoRT algorithm can accurately discriminate cardiovascular disease risk for a wide range of health profiles without the aid of clinical measures. Such algorithms hold potential to support precision medicine for individual or population uses. Study

2018 EvidenceUpdates

179. Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register Full Text available with Trip Pro

Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register To evaluate the performance of five cardiovascular disease (CVD) risk scores developed in diabetes populations and compare their performance to QRISK2.A cohort of people diagnosed with type 2 diabetes between 2004 and 2016 was identified from the Scottish national diabetes register. CVD events were identified using linked (...) hospital and death records. Five-year risk of CVD was estimated using each of QRISK2, ADVANCE (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation), Cardiovascular Health Study (CHS), New Zealand Diabetes Cohort Study (NZ DCS), Fremantle Diabetes Study, and Swedish National Diabetes Register (NDR) risk scores. Discrimination and calibration were assessed using the Harrell C statistic and calibration plots, respectively.The external validation cohort consisted

2018 EvidenceUpdates

180. Cardiovascular Disease: Secondary Prevention

Cardiovascular Disease: Secondary Prevention © 1996 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 0 Atherosclerotic Cardiovascular Disease (ASCVD) Secondary Prevention Guideline Major Changes as of April 2018 2 Definitions 2 Target Population 2 Goals 2 Lifestyle Modifications 3 Dietary Supplements 4 Influenza Vaccination 4 Statin Therapy 4 ACE Inhibitor or ARB Therapy 9 Antiplatelet Therapy 9 Lowering Triglycerides to Prevent Pancreatitis 10 Beta-blocker Therapy for Post (...) is patients who have been diagnosed with ASCVD. This guideline addresses treatment of underlying ASCVD only, and does not address treatment of any associated conditions. Goals Reduce recurrent cardiovascular events and decrease coronary mortality. 3 Lifestyle Modifications Tobacco cessation • Ask patients about tobacco use at every office visit. • Advise tobacco users to quit. • Advise patients at every office visit to avoid exposure to environmental tobacco smoke at home, work, and in public places

2018 Kaiser Permanente Clinical Guidelines